Lublin F, Miller DH, Freedman MS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2016; 387: 1075–84—In this Article, the list of principal investigators in the appendix has been updated. This correction has been made to the online version as of Jan 19, 2017.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jEPv6S
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Background A reported penicillin allergy may compromise receipt of recommended antibiotic prophylaxis intended to prevent surgica...
-
Related Articles Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol:...
-
Rejuvenation Research , Vol. 0, No. 0. from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2EFILxo via I...
-
Letter to the editor of Acta Neurochirurgica: simultaneous pericranial and nasoseptal "double-flap" reconstruction after comb...
-
Abstract The core mission of the Early Stage Professionals in Molecular Imaging Sciences (ESPMIS) Interest Group is to help young scientist...
-
Adenylyl Cyclase-Associated Protein 1 in the Development of Head and Neck Squamous Cell Carcinomas. Bull Exp Biol Med. 2016 Mar 29; A...
-
In view of the performance requirements (e.g., ride comfort, road holding, and suspension space limitation) for vehicle suspension systems, ...
-
Ravikiran N Pawar, Sambhunath Banerjee, Subhajit Bramha, Shekhar Krishnan, Arpita Bhattacharya, Vaskar Saha, Anupam Chakrapani, Saurabh Bhav...
-
Purpose: This phase I study aimed to determine the recommended dose (RD), safety profile, and feasibility of a procedure combining intratum...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου